Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Holding NKTR?
Track your performance easily
NKTR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.46 - $1.93
Previous Close$1.01
Volume1.03M
Average Volume (3M)1.73M
Market Cap
$186.30M
Enterprise Value$50.07M
Total Cash (Recent Filing)$244.50M
Total Debt (Recent Filing)$108.26M
Price to Earnings (P/E)―
Beta2.71
Next Earnings
Feb 27, 2025EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding184,458,284
10 Day Avg. Volume2,650,306
30 Day Avg. Volume1,727,758
Standard Deviation0.19
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)3.74
Price to Sales (P/S)2.00
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.54
Enterprise Value/Gross Profit0.89
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$5.83Price Target Upside483.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Nektar Therapeutics News
PremiumCompany Announcements
Nektar Therapeutics Reports Stable Q3 Earnings for 2024
Ownership Overview
10.79% Insiders
19.37% Mutual Funds
35.49% Other Institutional Investors
23.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $0.46 and its highest was $1.93 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Currently, no data Available
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 68 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.199 by $0.019.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -$0.13.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 184,458,280 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.199. Following the earnings report the stock price went up 2.19%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Among the largest hedge funds holding Nektar Therapeutics’s share is PRIMECAP Management Co. It holds Nektar Therapeutics’s shares valued at 8M.
---
Nektar Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.83 (483.00% Upside)
$5.83 (483.00% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 992.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 11.7%
Last 30 Days ▼ 11.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
102.81%
12-Months-Change
Fundamentals
Return on Equity
-161.63%
Trailing 12-Months
Asset Growth
-30.36%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
---
NKTR Earnings Call
Q3 2024
0:00 / 0:00
---
NKTR Stock 12 Month Forecast
Average Price Target
$5.83
▲(483.00% Upside)
Technical Analysis
Best Analysts Covering NKTR
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+54.19%
reiterated a sell rating 7 months ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +54.19% per trade.
---